Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial.

Introduction: A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005.

Cardiopulmonary exercise testing in children with cystic fibrosis: one centre's experience.

Background: While exercise testing is increasingly used as a prognostic indicator in cystic fibrosis (CF), it is reported to be underused in UK CF centres, particularly in children. Here, we evaluated the cardiopulmonary exercise testing (CPET) results in children and young people with CF at CF annual review and its possible clinical value.

Method: An observational study comparing CPET results using a cycle ergometer ramp test (peak oxygen uptake (Vo)) and pulmonary function (forced expiratory volume in 1 s (FEV)) was performed with body mass index (BMI) used as a disease severity marker.